SunBio, Inc. Logo

SunBio, Inc.

Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.

067370 | KO

Overview

Corporate Details

ISIN(s):
KR7067370007
LEI:
Country:
South Korea
Address:
인천광역시 남동구 은봉로 129 -, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SunBio, Inc. is a biotechnology company that develops, produces, and commercializes biosimilars, biopharmaceuticals, and medical devices. The company's core research and development activities are based on its proprietary PEGylation technology, a platform used to enhance the efficacy and duration of therapeutic drugs. Key products in its pipeline include an artificial blood substitute and MucoPEG, a treatment for xerostomia (dry mouth).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-06-26 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 61.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-07 00:00
Share Issue/Capital Change
전환가액의조정 (제4회차)
Korean 10.7 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.5 KB
2025-03-31 00:00
Regulatory News Service
본점소재지변경
Korean 5.8 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-24 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.8 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 353.1 KB
2025-03-21 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.3 MB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 94.4 KB
2025-03-12 00:00
Audit Report / Information
감사보고서제출
Korean 18.8 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.0 KB
2025-02-12 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.4 KB
2024-12-11 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB

Automate Your Workflow. Get a real-time feed of all SunBio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SunBio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SunBio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom
KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN

Talk to a Data Expert

Have a question? We'll get back to you promptly.